Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Accumulated Expenses (2020 - 2025)

Lyell Immunopharma's Accumulated Expenses history spans 6 years, with the latest figure at $29.3 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 1.04% year-over-year to $29.3 million; the TTM value through Sep 2025 reached $29.3 million, up 1.04%, while the annual FY2024 figure was $40.8 million, 45.14% up from the prior year.
  • Accumulated Expenses for Q3 2025 was $29.3 million at Lyell Immunopharma, up from $28.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $40.8 million in Q4 2024 and bottomed at $21.4 million in Q2 2022.
  • The 5-year median for Accumulated Expenses is $26.8 million (2024), against an average of $27.2 million.
  • The largest annual shift saw Accumulated Expenses fell 16.32% in 2022 before it skyrocketed 45.14% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $29.1 million in 2021, then decreased by 1.04% to $28.8 million in 2022, then dropped by 2.19% to $28.1 million in 2023, then skyrocketed by 45.14% to $40.8 million in 2024, then fell by 28.2% to $29.3 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Accumulated Expenses are $29.3 million (Q3 2025), $28.0 million (Q2 2025), and $31.2 million (Q1 2025).